文献速递白血病

费城染色体阳性慢性髓性白血病患者停用酪氨酸激酶抑制剂后的无治疗缓解

Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors.
PubMed 文献 · Am J Hematol · 2022-04-07

该研究分析了1999年10月至2017年2月间停用酪氨酸激酶抑制剂(TKI)的费城染色体阳性慢性髓性白血病(Ph阳性CML)患者,共284例,其中199例(70%)为选择性停药。中位随访36个月(95%CI 32-40)后,53例(19%)失去主要分子学缓解(MMR),估计5年无治疗缓解(TFR)率为79%。停药前达到MR4或MR4.5持续≥5年与更低的MMR丢失风险相关。

要点

  • Ph阳性CML患者停用TKI后估计5年TFR率为79%。
  • 停药前MR4或MR4.5持续≥5年者5年TFR率高于MR4持续<5年者(87% vs 92% vs 64%,p<.0001)。
  • 多变量分析显示仅MR4或MR4.5持续≥5年与较低的MMR丢失风险相关。

核心结论

  • 在Ph阳性CML接受TKI治疗的患者中,TFR是安全可行的。
  • 达到MR4或MR4.5至少5年与更好的结局相关。

研究设计与样本

  • 回顾性分析1999年10月至2017年2月期间停用TKI的Ph阳性CML患者,共284例,其中199例(70%)为选择性停药。
  • MMR定义为国际标准化的BCR-ABL1/ABL1比值≤0.1%。
  • TFR失败定义为任何一次检测失去MMR。

主要发现

  • 中位随访36个月(95%CI 32-40)后,53例(19%)失去MMR。
  • 估计5年TFR率为79%。
  • 除1例以外,所有失去MMR的患者在恢复治疗后重新获得MMR。
  • 停药前MR4持续≥5年、MR4.5持续≥5年与MR4持续<5年相比,估计5年TFR率分别为87%、92%和64%(p<.0001)。
  • 多变量分析显示,仅停药前MR4或MR4.5持续≥5年与较低的MMR丢失风险相关。

关键数值与推荐

  • MMR定义为BCR-ABL1/ABL1比值(国际标准)≤0.1%。
  • TFR失败定义为任何一次检测失去MMR。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tyrosine kinase inhibitors (TKIs) discontinuation in patients with Philadelphia-chromosome-positive chronic myeloid leukemia (Ph-positive CML) is increasingly considered. We aim to evaluate the outcome of patients with CML who discontinued TKIs, and determine the factors associated with differences in the success rates of treatment-free remission (TFR). Patients with Ph-positive CML treated between October 1999 and February 2017 who discontinued therapy were analyzed. A major molecular response (MMR) was defined as BCR-ABL1/ABL1 ratio on the International Scale ≤0.1%. TFR failure was defined as the loss of MMR on any single test. We analyzed TFR rates according to duration and depth of response, and conducted a multivariate analysis for factors associated with loss of MMR. Two-hundred and eighty-four patients were analyzed; 199 patients (70%) electively discontinued TKIs. At a median follow-up of 36 months (95% confidence interval, 32-40) after TKI discontinuation, 53 patients (19%) lost MMR. The estimated 5-year TFR rate was 79%. All but one patient regained MMR after resuming therapy. The estimated 5-year TFR rates were higher with MR4 and MR4.5 ≥5 years, compared with MR4 <5 years (87% vs. 92% vs. 64%; p < .0001). By multivariate analysis, only the duration of MR4 or MR4.5 ≥5 years before stopping treatment was associated with a lower risk of loss of MMR. In summary, TFR is safe and feasible in patients with Ph-positive CML on TKI therapy. Achieving MR4 or MR4.5 for at least 5 years is correlated with a better outcome.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Haddad FG, Sasaki K, Issa GC, et al. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. Am J Hematol. 2022. PMID: 35357036. doi:10.1002/ajh.26550

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。